 |
06/15/2009
PTC THERAPEUTICS RECEIVES $2.6 MILLION IN GOVERNMENT GRANTS
|
11.4 KB |
| |
SOUTH PLAINFIELD, NJ - June 15, 2009 - PTC Therapeutics, Inc. (PTC) today announced the receipt of two government grants to support clinical development programs in rare disorders. The U.S. Department of Defense Neurofibromatosis Research Program has awarded an $822,345 grant to support a new open-label Phase 2 clinical trial of PTC's pro...
|
|
06/01/2009
PTC THERAPEUTICS APPOINTS CLARE KENNEDY AS VICE PRESIDENT OF COMMERCIAL OPERATIONS
|
8.2 KB |
| |
SOUTH PLAINFIELD, NJ - June 1, 2009 - PTC Therapeutics, Inc. (PTC) today announced that Clare Kennedy has been appointed as Vice President of Commercial Operations. In this role, she will be reporting to Theresa Natalicchio, Senior Vice President, Commercial, and be responsible for company's patient services and distribution functions foc...
|
|
05/12/2009
PTC THERAPEUTICS AND SPINAL MUSCULAR ATROPHY FOUNDATION ANNOUNCE $8.5 MILLION SMALL MOLECULE DEVELOPMENT COLLABORATION
|
10.1 KB |
| |
SOUTH PLAINFIELD, NJ AND NEW YORK, NY - May 12, 2009 - PTC Therapeutics, Inc. (PTC) and the Spinal Muscular Atrophy (SMA) Foundation today announced the expansion of their research collaboration in which the SMA Foundation will provide up to $8.5 million in funding to PTC. This is the second continuation of the collaboration to fund a ser...
|
|
02/03/2009
PTC THERAPEUTICS COMPLETES ENROLLMENT OF PIVOTAL TRIAL IN MUSCULAR DYSTROPHY
|
13.1 KB |
| |
SOUTH PLAINFIELD, NJ - February 3, 2009 - PTC Therapeutics, Inc. (PTC) today announced that it has successfully completed patient enrollment of its pivotal clinical trial of PTC124 in patients with nonsense mutation Duchenne and Becker muscular dystrophy (nmDMD/BMD). Accrual was completed two months ahead of schedule. The company also ann...
|
|
|